WA
TXMD icon

WFG Advisors’s TherapeuticsMD TXMD Stock Holding History

WFG Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$80K Buy
302
+68
+29% +$17K 0.02% 581
2017
Q1 		$84K Sell
234
-124
-35% -$38.4K 0.02% 537
2016
Q4 		$103K Buy
+358
New +$111K 0.03% 519

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

WFG Advisors's TXMD Position: Q2 2017 in Review

WFG Advisors increased its TherapeuticsMD (TXMD) stake by 29% in Q2 2017, buying an estimated $17K and bringing the position to 302 shares worth $80K. The position accounts for 0.02% of the portfolio, ranked #581.

WFG Advisors first reported a position in TXMD in Q4 2016 and has held it in 3 quarters since. The position peaked at $103K in Q4 2016. 117 funds tracked by Wall St. Rank hold TXMD as of Q2 2017.

  • WFG Advisors held 302 shares of TherapeuticsMD worth $80K as of Q2 2017.
  • WFG Advisors bought 68 TherapeuticsMD shares in Q2 2017, an estimated $17K.
  • TherapeuticsMD made up 0.02% of WFG Advisors's portfolio in Q2 2017, its #581 holding.
  • WFG Advisors first reported a position in TherapeuticsMD in Q4 2016 and has held it in 3 quarters since.
  • WFG Advisors's TherapeuticsMD position peaked at $103K in Q4 2016.
  • 117 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.